Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
ISO 28820:2009 — Medical devices — Needle-based injection systems
Foundational terminology, classification, and general safety requirements for needle-based medical injection systems
ISO 28820:2009 establishes the foundational terminology, classification, and general safety requirements for needle-based injection systems used in medical practice. It serves as the root document for the ISO 28820 series, defining common performance characteristics applicable to all subsequent parts.
1. Scope and Classification of Needle-Based Injection Systems
ISO 28820:2009 defines a needle-based injection system as a medical device assembly comprising a container (syringe barrel, cartridge, or prefilled syringe), a needle assembly (hub, cannula, and protective cap), and an actuation mechanism (plunger, piston, or automated injector). The standard covers single-use and reusable devices intended for subcutaneous, intramuscular, intradermal, and intravenous administration of liquid medications, including vaccines, insulin, anaesthetics, and biologics.
The standard classifies injection systems by several parameters: delivery mechanism (manual, spring-assisted, or power-driven), needle configuration (fixed-needle, luer-lock, or retractable), container type (prefilled syringe, fill-your-own cartridge, or dual-chamber for lyophilised drugs), and intended use environment (clinical, home-care, or emergency field use). Each classification axis drives specific design requirements for biocompatibility, dose accuracy, sterility maintenance, and ease of use for the target patient population.
Engineers designing needle-based injection systems must pay careful attention to the classification boundary between “manual” and “power-driven” devices. A spring-assisted autoinjector that stores energy for needle insertion but relies on manual plunger force for drug delivery falls into an intermediate category requiring additional safety analysis under ISO 28820 and the applicable risk management standard ISO 14971.
| Classification Parameter | Categories | Key Design Implications |
|---|---|---|
| Delivery mechanism | Manual, spring-assisted, power-driven | Force profile, velocity control, trigger safety |
| Needle configuration | Fixed, luer-lock, retractable, shielded | Sharps injury prevention, connection reliability |
| Container type | Prefilled syringe, cartridge, dual-chamber | Drug stability, reconstitution mechanism, shelf life |
| Intended user | Healthcare professional, patient self-injection | Ergonomics, training needs, use error mitigation |
| Dose range | Fixed dose, variable dose, multi-dose | Dose setting mechanism, accuracy verification |
2. General Safety Requirements and Performance Criteria
ISO 28820 establishes mandatory safety requirements that apply to all needle-based injection systems regardless of classification. The most fundamental requirement is dose accuracy: the delivered volume must be within ±5 % of the indicated dose for volumes ≥ 1 mL, and within ±10 % for volumes < 1 mL, across the full range of operating conditions including temperature extremes, orientation variations, and user-induced force variations. This requires careful design of the plunger-barrel seal interface, air-elimination features, and end-of-stroke detection mechanisms.
Biocompatibility requirements follow the ISO 10993 series: all patient-contacting materials — including the syringe barrel, plunger stopper, needle cannula, and any lubricants — must undergo cytotoxicity, sensitisation, and irritation testing as a minimum. For devices that contact blood or tissue for extended periods, additional testing for acute systemic toxicity, subacute toxicity, and hemocompatibility is required. The standard also mandates extractables and leachables studies for drug-contacting surfaces, as the interaction between the container and the drug formulation can affect both drug stability and patient safety.
A well-designed plunger stopper formulation is critical for both dose accuracy and biocompatibility. Bromobutyl rubber stoppers with fluoropolymer laminate coatings offer an excellent balance of low extractables, consistent glide force, and robust seal integrity across the device shelf life. When specifying a stopper material, always conduct a functional compatibility study with the target drug formulation under accelerated aging conditions (40 °C / 75 % RH for 6 months per ASTM F1980).
| Requirement | Acceptance Criterion | Test Method | Relevant Standard |
|---|---|---|---|
| Dose accuracy (≥ 1 mL) | ±5 % of indicated volume | Gravimetric measurement | ISO 7886-1 |
| Dose accuracy (< 1 mL) | ±10 % of indicated volume | Gravimetric measurement | ISO 7886-1 |
| Plunger glide force | ≤ 15 N dynamic, ≤ 30 N break-loose | Force-displacement test | ISO 7886-1 |
| Needle sharpness | Penetration force ≤ 0.5 N (26G) | Penetration force test | ISO 7864 |
| Sterile barrier integrity | No leak after vacuum test | Dye ingress / bubble test | ISO 11607-1 |
| Dead volume | Minimised per design target | Water displacement | — |
3. Design Validation and Human Factors Engineering
ISO 28820 requires that manufacturers conduct design validation through a combination of simulated-use testing, clinical evaluation, and human factors engineering studies. The simulated-use testing must cover the full range of intended-use scenarios: preparation (filling or attaching the needle), air removal, dose setting (for variable-dose devices), injection administration, and safe disposal. Each step must be evaluated for use errors, particularly those that could lead to underdose, overdose, needlestick injury, or contamination.
Human factors validation per IEC 62366 is a key requirement for patient-administered devices. The standard expects manufacturers to conduct formative usability studies with representative users (including elderly patients, those with reduced manual dexterity, and visually impaired individuals), identify use-related hazards, and implement design mitigations. The summative validation study must demonstrate that the critical tasks can be performed safely and effectively by the intended user population without unacceptable use errors.
Needlestick injury prevention is one of the most critical design considerations under ISO 28820. For devices intended for clinical use, passive safety mechanisms (those that activate automatically as part of the injection sequence) are strongly preferred over active mechanisms (those requiring a separate user action). A recent study by the WHO found that passive safety-engineered syringes reduced needlestick injuries by 85 % compared to conventional syringes, compared to only 45 % for active safety devices.
Frequently Asked Questions
Q1: How does ISO 28820 relate to ISO 7886 (sterile hypodermic syringes)?
ISO 7886 specifies requirements for individual sterile hypodermic syringes and is a key referenced standard within ISO 28820. ISO 28820 takes a broader systems-level approach, covering the complete injection device including container, needle, actuation mechanism, and any safety features, whereas ISO 7886 focuses primarily on the syringe barrel and plunger.
Q2: Does ISO 28820 cover autoinjectors and pen injectors?
Yes, the standard’s scope includes all needle-based injection systems regardless of actuation mechanism. Autoinjectors, pen injectors, and wearable injectors are covered by ISO 28820 as long as they use a needle for drug delivery. Needle-free injectors are explicitly excluded and are covered by ISO 28823.
Q3: What are the shelf-life testing requirements?
The standard requires real-time and accelerated aging studies to establish the device shelf life. For sterile devices, the sterility barrier integrity must be maintained throughout the claimed shelf life. Functional parameters — glide force, dose accuracy, needle sharpness, and seal integrity — must be verified at end of shelf life.
Q4: How are lubricants addressed?
Silicone oil (typically polydimethylsiloxane) is the most common lubricant used on syringe barrels and stoppers. ISO 28820 requires that the lubricant be biocompatible per ISO 10993, that its quantity and distribution be controlled and verified, and that it not interfere with the drug formulation. Alternative dry-coating technologies (e.g., plasma-deposited PTFE-like coatings) are gaining acceptance as they eliminate silicone-related particle and leachable concerns.
